How can you improve your success and strategies in myopia management? Considering the individual’s family situation and risk factors is key to providing the ideal solution that will ensure suitability and compliance.
Will China’s new regulations restricting online gaming in children reduce the myopia crisis? Is there evidence that less screen time increases outdoor time? We explore the links and impacts, positive effects of gaming and advice for parents.
Myopia controlling contact lenses offer numerous benefits for children. How can you select the most appropriate option, specific to the individual child and their family? Explore these key questions in clinical communication to learn more.
How should you best manage children with unilateral or anisometropic myopia? Learn about what drives aniso-myopic development, associations with amblyopia and ocular pathology, and the evidence base for orthokeratology to slow aniso-myopic eye growth.
What amount of axial length growth be expected in myopes versus emmetropes, and how can you tell if your myopia control treatment is working? This important clinical reference provides all this information and more on axial growth in younger and older children, emmetropes and myopes, and even data on typical myopia stabilization.
There is no one-size-fits-all when prescribing for childhood myopia control. Which option should you choose? In this important reference article, we ask you to consider three key questions which form clinical decision trees in myopia management.
Managing myopia in presbyopic adults has specific goals in achieving good vision correction and best eye health outcomes. What should we consider if myopia progression is observed? This article explores progression, the ideal optical correction and ocular health considerations in presbyopic myopes.
Orthokeratology has been well established as a myopia control treatment. The newest research in orthokeratology has investigated compliance, safety, comfort and combination treatment with atropine. Here, we’ll bring you the latest knowledge with implications for clinical practice.
Atropine has been the apparent hero of myopia management since the 2006 ATOM1 study, and since then, low concentration 0.01% atropine has become the new hero and then fallen out of favour. This article describes how lower concentrations work to balance efficacy and side effects, which should we select now, and what newer research on formulations and combinations can tell us.
Binocular vision is a much neglected (and even maligned?) domain of eye care where I’ve had numerous colleagues say their professional excitement and learning opportunities have been reinvigorated through seeing the clinical imperative and application in practice. Not only does binocular vision assessment add so much more to your clinical picture, and make optometric life more interesting, it could be the secret sauce that helps us bridge the gap towards 100% efficacy.
